23Andme, Inc.

Wei-Jen Chung

Yu Chen

Erik E Karrer

Germaine Fuh-Kelly

Yao-ming Huang

Louise Scharf

Steven J Pitts

Cecilia Lay

Jilean Beth Fenaux

Germaine G Fuh

Patrick Koenig

Shruti Yadav

Claus Spitzfaden

Yujie Liu

Ping-Chiao Tsai

I-Ling Chen

Joel Benjamin

Shashank Bharill

Mauro Poggio

Zahra Bahrami Dizicheh

The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.

Anti-CD200R1 antibodies and methods of use thereof

The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.

Anti-ULBP6 antibodies

Growing community of inventors

El Granada, CA, United States of America

Wei-Jen Chung